The answer turned out to be a cutting-edge treatment that few Americans know about, according to Roswell Park Comprehensive ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company's lead candidate, HyBryte(TM ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted ... promising progression-free ...

and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the ...

Mangione's lawyer, Karen Friedman Agnifilo, has argued that Mangione can't mount a defense if he has to store all of the 15,000 pages of disclosed prosecution evidence in his New York prison cell.

CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to ...

The 17-year-old collapsed unconscious at the gym, where staff rushed to his aid and quickly realised he didn't have a pulse ... advances in response and survival rates across the state have ...

Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders. Wojciech Jurczak, MD, PhD, head of the department of ...